CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Phase 2
Recruiting
- Conditions
- B-cell Non Hodgkin Lymphoma
- Interventions
- Other: autologous stem-cell transplantationDrug: Relmacabtagene autoleucel (relma-cel)
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT06365671
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
An Evaluation of LY007 Cell Injection for r/r B-NHL
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06364852
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, China
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06363084
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Phase 3
Recruiting
- Conditions
- Esophageal Cancer
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 356
- Registration Number
- NCT06339060
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, China
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
Not Applicable
Recruiting
- Conditions
- Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Drug: CMGV
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06329999
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
Not yet recruiting
- Conditions
- Neurodegenerative DiseasesCognitive ImpairmentAlzheimer DiseaseMild Cognitive Impairment
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1872
- Registration Number
- NCT06325527
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Phase 2
Recruiting
- Conditions
- Antiphospholipid Syndrome (APS)
- Interventions
- Drug: Telitacicept+SOCDrug: SOC
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06315530
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Phase 3
Not yet recruiting
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT06297772
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06269211
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Phase 3
Not yet recruiting
- Conditions
- Extranodal Natural Killer T Cell Lymphoma
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 142
- Registration Number
- NCT06255795
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath